USC.edu
Are You a Patient?

Michael Frederick Press, MD, PhD

Professor of Pathology

Harold E. Lee Chair in Breast Cancer Research

Director of Breast Cancer Analysis Lab

Image of Michael Frederick Press, MD, PhD
Websites
Is this your profile? Click to edit
Phone +1 323 865 0563
Email [email protected]
CTSI Profile

Overview

Michael F. Press, M.D., Ph.D. is a professor in the Department of Pathology and co-leader of the Women’s Cancers Program. He received his M.D., Ph.D. and residency training at the University of Chicago. He was a member of the University of Chicago faculty for seven years before joining the faculty of the University of Southern California in 1988. Dr. Press is currently the director for the Breast Cancer International Research Group Central Laboratory, the coordinator of the Breast Cancer Program at USC Norris Cancer Center and holds the Harold E. Lee Chair in Cancer Research in the USC Norris Cancer Center. His research interests are molecular genetic alterations in breast and gynecologic cancers.

Research Funding

  • HER-2 NEU PROTO-ONCOGENE IN OVARIAN &ENDOMETRIAL CANCER
    NIH · R01CA050589 · Feb 1, 1991 – Jan 31, 1995 · Role: Principal Investigator
  • PATHOBIOLOGY OF BREAST CANCER AND HORMONE RECEPTORS
    NIH · R01CA048780 · Apr 1, 1988 – Jan 31, 2006 · Role: Principal Investigator

Publications

  • A comprehensive examination of breast cancer risk loci in African American women. Hum Mol Genet. 2014 Oct 15; 23(20):5518-26.. View in PubMed
  • HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. Breast Cancer Res Treat. 2014 May; 145(1):193-203.. View in PubMed
  • Meta-analysis of loci associated with age at natural menopause in African-American women. Hum Mol Genet. 2014 Jun 15; 23(12):3327-42.. View in PubMed
  • Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Methods Mol Biol. 2014; 1180:181-207.. View in PubMed
  • Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2014 Feb 01; 20(3):736-43.. View in PubMed
  • Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014 Feb; 138(2):241-56.. View in PubMed
  • Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 01; 31(31):3997-4013.. View in PubMed
  • A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med. 2013 Dec 20; 32(29):5039-52.. View in PubMed
  • Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer. 2013 May 04; 13:225.. View in PubMed
  • Genome-wide association study of age at menarche in African-American women. Hum Mol Genet. 2013 Aug 15; 22(16):3329-46.. View in PubMed

Similar People